Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 600

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 600
---
 used in operating activities            |     |                         | (29,729 | ) |     |      |  (35,747 | ) |
| Financing activities:                            |     |                         |         |   |     |      |          |   |
| Proceeds from issuance of preferred units        |     |                         |       - |   |     |      |   50,000 |   |
| Cash provided by financing activities            |     |                         |       - |   |     |      |   50,000 |   |
| Net (decrease) increase in cash                  |     |                         | (29,729 | ) |     |      |   14,253 |   |
| Cash, beginning of year                          |     | $                       |  77,952 |   |     |      |   63,699 |   |
| Cash, end of year                                |     | $                       |  48,223 |   |     | $    |   77,952 |   |
| Supplemental disclosure of cash flow information |     |                         |         |   |     |      |          |   |
| Cash paid for interest during the year           |     | $                       |       - |   |     | $    |        - |   |
| Cash paid for taxes during the year              |     | $                       |       - |   |     | $    |        - |   |

The accompanying notes are an integral part of these financial statements.

| F-81 |

aegeria soft tissue llc

notes to the financial statements

December 31, 2023 and 2022

Note 1 - Organization and Description of Business

Aegeria Soft Tissue LLC (“Aegeria” or the “Company”), is a clinical-stage regenerative medicine company based in Baltimore, Maryland, USA. Aegeria is incorporated in the state of Delaware and is run virtually with no employees, customers, or offices. The Company has an exclusive worldwide license of a biomatrix technology developed at Johns Hopkins University (“JHU”). The platform biomatrix is designed for soft tissue reconstruction and the lead clinical program focuses on the treatment of soft tissue defects including aesthetics and lumpectomy defects.

The Company’s operations are solely for advancing and commercializing the licensed technology. Proceeds from the issuance of equity and debt to our member investors has been used to pay for manufacturing development and internal direct costs such as legal, insurance, accounting, tax, and subcontractors.